Biogen prices ALS therapy Qalsody at $14K a dose - report
funky-data         
Biogen has set a price for its recently approved ALS therapy Qalsody (tofersen) at $14,230 per dose.
Given that 14 doses are required in the first year of treatment, that comes out to just under $200K for the first year alone, Endpoints News reported. Subsequent years require 13 doses, a cost of ~$185K.
Qalsody's cost is more than that of another recently approved ALS treatment,Â Amylyx Pharmaceuticals' (AMLX) Relyvrio (sodium phenylbutyrate/taurursodiol), which is priced at $158K annually.
FDA advisors expressed concern in March that the data provided by Biogen (NASDAQ:BIIB) did not demonstrate convincing evidence of tofersen's benefit.